Skip to main
LMAT

LeMaitre Vascular (LMAT) Stock Forecast & Price Target

LeMaitre Vascular (LMAT) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

LeMaitre Vascular is well-positioned for future growth due to a strong financial position, with approximately $367 million in cash and marketable securities and strong operating cash flow. The company is focused on expanding its presence in the lucrative cardiac space and is pursuing external growth opportunities through acquisitions. Additionally, the company has demonstrated consistent double-digit organic top-line growth with material margin expansion and has a strong portfolio of products used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease.

Bears say

LeMaitre Vascular is seeing strong growth in its top and bottom line, with double-digit organic revenue growth, 350 bps expansion in gross margin, and a 41% increase in operating income. The company's focus on developing and marketing vascular devices for various surgical specialties has resulted in a diversified revenue stream. However, the increase in operating expenses and higher sales and marketing expense as a percentage of revenue may impact the company's profitability in the long term. Additionally, the company's debt of $169 million and continued investments in research and development may impact its cash flow.

LeMaitre Vascular (LMAT) has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LeMaitre Vascular and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LeMaitre Vascular (LMAT) Forecast

Analysts have given LeMaitre Vascular (LMAT) a Buy based on their latest research and market trends.

According to 4 analysts, LeMaitre Vascular (LMAT) has a Buy consensus rating as of Sep 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $114.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $114.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LeMaitre Vascular (LMAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.